External referencing and pharmaceutical price negotiation

Begoña Garcia Mariñoso, Izabela Jelovac, Pau Olivella

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

External referencing (ER) imposes a price cap for pharmaceuticals, based on prices of identical or comparable products in foreign countries. Suppose a foreign country (F) negotiates prices with a pharmaceutical firm, whereas a home country (H) can either negotiate prices independently or implement ER, based on the foreign price. We show that country H prefers ER if copayments in H are relatively high. This preference is reinforced when H's population is small. Irrespective of relative country sizes, ER by country H harms country F. Our model is inspired by the wide European experience with this cost-containment policy. Namely, in Europe, drug authorization and price negotiations are carried out by separate agencies. We confirm our main results in two extensions. The first one allows for therapeutic competition between drugs. In the second one, drug authorization and price negotiation take place in a single agency. Copyright © 2010 John Wiley & Sons, Ltd.
Original languageEnglish
Pages (from-to)737-756
JournalHealth Economics (United Kingdom)
Volume20
DOIs
Publication statusPublished - 1 Jun 2011

Keywords

  • External referencing
  • Pharmaceuticals
  • Price negotiation

Fingerprint Dive into the research topics of 'External referencing and pharmaceutical price negotiation'. Together they form a unique fingerprint.

Cite this